Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th
Company to host an investor conference call and webcast at 4:30pm EDT
NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced that the Company will release financial results for the second quarter ended June 30, 2024 on Monday, August 12th, 2024, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. ET to review the financial and operating results.
Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) and reference Conference ID# 13747356.
To access the Call me™ feature, which avoids having to wait for an operator, click .
A live webcast of the conference call will also be available and on the investor relations page of the Company's corporate website at .
After the live webcast, the event will be archived on Eyenovia’s website for one year.
About Eyenovia, Inc.
Eyenovia, Inc. is an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis, Clobetasol Propionate Ophthalmic Suspension, 0.05% for postsurgical inflammation and pain, and developing the Optejet® device for use both in connection with its own drug-device therapeutic product for pediatric progressive myopia as well as out-licensing for additional indications. For more information, please visit Eyenovia.com.
For more information, visit .
The Eyenovia Corporate Information slide deck may be found at .
Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
(646) 751-4363
Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
